JP2021119797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021119797A5 JP2021119797A5 JP2021089151A JP2021089151A JP2021119797A5 JP 2021119797 A5 JP2021119797 A5 JP 2021119797A5 JP 2021089151 A JP2021089151 A JP 2021089151A JP 2021089151 A JP2021089151 A JP 2021089151A JP 2021119797 A5 JP2021119797 A5 JP 2021119797A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- recombinant hsv
- cell
- composition
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700584 Simplexvirus Species 0.000 claims 31
- 210000004027 cell Anatomy 0.000 claims 20
- 101150027427 ICP4 gene Proteins 0.000 claims 8
- 108091056924 miR-124 stem-loop Proteins 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000010076 replication Effects 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 108091070501 miRNA Proteins 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 108700005077 Viral Genes Proteins 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 101710130522 mRNA export factor Proteins 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101150090364 ICP0 gene Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 101150041636 NEC1 gene Proteins 0.000 claims 2
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 101150072608 CVC1 gene Proteins 0.000 claims 1
- 101150010802 CVC2 gene Proteins 0.000 claims 1
- 101150026402 DBP gene Proteins 0.000 claims 1
- 101150109586 Gk gene Proteins 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101150064935 HELI gene Proteins 0.000 claims 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 1
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims 1
- 101100427508 Human cytomegalovirus (strain AD169) UL39 gene Proteins 0.000 claims 1
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 claims 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 claims 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 101150047390 MCP gene Proteins 0.000 claims 1
- 108091007780 MiR-122 Proteins 0.000 claims 1
- 101150098384 NEC2 gene Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 101150093191 RIR1 gene Proteins 0.000 claims 1
- 101150030723 RIR2 gene Proteins 0.000 claims 1
- 101150027249 RL1 gene Proteins 0.000 claims 1
- 101150103019 SCP gene Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 101150110861 TRM2 gene Proteins 0.000 claims 1
- 101150048584 TRM3 gene Proteins 0.000 claims 1
- 101150102071 TRX1 gene Proteins 0.000 claims 1
- 101150037769 TRX2 gene Proteins 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 101150111135 UL1 gene Proteins 0.000 claims 1
- 101150087840 UL11 gene Proteins 0.000 claims 1
- 101150023763 UL12 gene Proteins 0.000 claims 1
- 101150036407 UL14 gene Proteins 0.000 claims 1
- 101150104047 UL17 gene Proteins 0.000 claims 1
- 101150109748 UL19 gene Proteins 0.000 claims 1
- 101150050388 UL20 gene Proteins 0.000 claims 1
- 101150004957 UL25 gene Proteins 0.000 claims 1
- 101150060044 UL26 gene Proteins 0.000 claims 1
- -1 UL26.5 Proteins 0.000 claims 1
- 101150003230 UL27 gene Proteins 0.000 claims 1
- 101150072074 UL28 gene Proteins 0.000 claims 1
- 101150008036 UL29 gene Proteins 0.000 claims 1
- 101150068034 UL30 gene Proteins 0.000 claims 1
- 101150019585 UL31 gene Proteins 0.000 claims 1
- 101150081727 UL32 gene Proteins 0.000 claims 1
- 101150017804 UL33 gene Proteins 0.000 claims 1
- 101150087430 UL34 gene Proteins 0.000 claims 1
- 101150023000 UL35 gene Proteins 0.000 claims 1
- 101150085237 UL36 gene Proteins 0.000 claims 1
- 101150036065 UL37 gene Proteins 0.000 claims 1
- 101150090946 UL38 gene Proteins 0.000 claims 1
- 101150100826 UL40 gene Proteins 0.000 claims 1
- 101150099321 UL42 gene Proteins 0.000 claims 1
- 101150004685 UL48 gene Proteins 0.000 claims 1
- 101150066971 UL49 gene Proteins 0.000 claims 1
- 101150099617 UL5 gene Proteins 0.000 claims 1
- 101150011902 UL52 gene Proteins 0.000 claims 1
- 101150009795 UL54 gene Proteins 0.000 claims 1
- 101150033660 UL6 gene Proteins 0.000 claims 1
- 101150095805 UL7 gene Proteins 0.000 claims 1
- 101150033561 UL8 gene Proteins 0.000 claims 1
- 101150026859 UL9 gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 101150029683 gB gene Proteins 0.000 claims 1
- 101150055782 gH gene Proteins 0.000 claims 1
- 101150015940 gL gene Proteins 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108091051828 miR-122 stem-loop Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 101150046896 trm1 gene Proteins 0.000 claims 1
Claims (19)
- 少なくとも２つの異なるｍｉＲ標的配列を含む組換え単純ヘルペスウイルス（ＨＳＶ）であって、前記組換えＨＳＶのゲノムのＩＣＰ４遺伝子座が少なくとも１つのｍｉＲ－１２４標的配列を含み、ＩＣＰ４以外のウイルス遺伝子の遺伝子座が少なくとも１つのｍｉＲ標的配列を含み、ＩＣＰ４以外の前記ウイルス遺伝子が、UL1、UL5、UL6、UL7、UL8、UL9、UL11、UL12、UL14、UL15、UL17、UL18、UL19、UL20、UL22、UL25、UL26、UL26.5、UL27、UL28、UL29、UL30、UL31、UL32、UL33、UL34、UL35、UL36、UL37、UL38、UL39、UL40、UL42、UL48、UL49、UL52、UL53、UL54、ICP0、ICP22、ICP27、ICP47、γ-34.5、US3、US4、US5、US6、US7、US8、US9、US10、US11およびUS12からなる群から選択される、組換えＨＳＶ。
- 前記少なくとも１つのｍｉＲ－１２４標的配列が、前記ＩＣＰ４遺伝子座の５’非翻訳領域（ＵＴＲ）または３’ＵＴＲに組み込まれる、請求項１に記載の組換えＨＳＶ。
- （ｉ）２つ以上のｍｉＲ－１２４標的配列が前記組換えＨＳＶゲノムの前記ＩＣＰ４遺伝子座に挿入される；または
（ｉｉ）ＩＣＰ４以外の前記ウイルス遺伝子がＩＣＰ２７である、
請求項１または請求項２に記載の組換えＨＳＶ。 - 前記組換えＨＳＶの複製が、第２の細胞における前記組換えＨＳＶの複製と比較して、第１の細胞において減少または減衰し、前記第１の細胞が正常細胞であり、前記第２の細胞ががん性細胞である、請求項１～３のいずれか一項に記載の組換えＨＳＶ。
- 前記第２の細胞におけるｍｉＲ－１２４の内因性発現が、前記第１の細胞におけるｍｉＲ－１２４の内因性発現と比較して減少する、請求項４に記載の組換えＨＳＶ。
- 前記第１の細胞における前記組換えＨＳＶの複製が、前記第２の細胞における前記組換えＨＳＶの複製と比較して、少なくとも５０％減少する、請求項５に記載の組換えＨＳＶ。
- 前記がん性細胞のがんが、大腸癌、膵癌、乳癌、肝癌、口腔癌、卵巣癌、前立腺癌、脳癌、子宮頸癌および肺癌からなる群から選択される、請求項４～６のいずれか一項に記載の組換えＨＳＶ。
- （ｉ）少なくとも１つの追加のｍｉＲ標的配列が前記ＩＣＰ４遺伝子座に組み込まれ、前記追加のｍｉＲ標的配列が、前記ｍｉＲ－１２４標的配列以外の配列である；または
（ｉｉ）少なくとも１つのｍｉＲ－１２２標的配列がＩＣＰ２７遺伝子座に組み込まれる、
請求項１～７のいずれか一項に記載の組換えＨＳＶ。 - サイトカインおよび抗免疫抑制タンパク質から選択されるタンパク質をコードする非相同ポリヌクレオチド配列をさらに含む、請求項１～８のいずれか一項に記載の組換えＨＳＶ。
- 前記サイトカインがＩＬ－１２であり、前記抗免疫抑制タンパク質が、抗ＰＤ１タンパク質および抗ＣＴＬＡ４タンパク質から選択される、請求項９に記載の組換えＨＳＶ。
- 前記非相同ポリヌクレオチド配列が、ＵＬ３とＵＬ４オープンリーディングフレームの間の前記組換えＨＳＶゲノムに挿入される、請求項９または請求項１０に記載の組換えＨＳＶ。
- 内部接合領域に、ＩＣＰ０、ＩＣＰ３４．５、ＬＡＴおよびＩＣＰ４遺伝子のそれぞれの１コピーの欠失をさらに含む、請求項１～１１のいずれか一項に記載の組換えＨＳＶ。
- 請求項１～１２のいずれか一項に記載の組換えＨＳＶをコードする核酸分子。
- 請求項１～１２のいずれかに記載の組換えＨＳＶを含むウイルスストック。
- 請求項１～１２のいずれかに記載の組換えＨＳＶと、薬学的に許容される担体とを含む、組成物。
- 医薬として使用するための、請求項１～１２のいずれかに記載の組換えＨＳＶを含む組成物または請求項１５に記載の組成物。
- がんの治療または予防における使用のための、請求項１～１２のいずれかに記載の組換えＨＳＶを含む組成物または請求項１５に記載の組成物。
- がんの治療または予防における使用のための、請求項８に記載の組換えＨＳＶを含む組成物であって、
（ｉ）前記治療または予防が、がん性細胞を、前記組換えＨＳＶが前記がん性細胞に感染し、当該がん性細胞内で複製するのに十分な条件に曝露することを含み、前記がん性細胞内での前記組換えＨＳＶの複製が細胞死をもたらすか；あるいは
（ｉｉ）対象がマウスまたはヒトであるか；あるいは
（ｉｉｉ）前記組成物が、静脈内、皮下、腫瘍内、または筋肉内投与されるか；あるいは
（ｉｖ）前記がんが、肺癌、乳癌、卵巣癌、子宮頸癌、前立腺癌、精巣癌、大腸癌、結腸癌、膵癌、肝癌、胃癌、頭頸部癌、甲状腺癌、悪性神経膠腫、膠芽腫、黒色腫、Ｂ細胞慢性リンパ球性白血病、びまん性大細胞型Ｂ細胞リンパ腫（ＤＬＢＣＬ）および辺縁帯リンパ腫（ＭＺＬ）から選択される、
組成物。 - 請求項１７に記載の使用のための組成物であって、
（ｉ）前記治療または予防が、がん性細胞を、前記組換えＨＳＶが前記がん性細胞に感染し、当該がん性細胞内で複製するのに十分な条件に曝露することを含み、前記がん性細胞内での前記組換えＨＳＶの複製が細胞死をもたらすか；あるいは
（ｉｉ）対象がマウスまたはヒトであるか；あるいは
（ｉｉｉ）前記組成物が、静脈内、皮下、腫瘍内、または筋肉内投与されるか；あるいは
（ｉｖ）前記組成物が、大腸癌、膵癌、乳癌、肝癌、口腔癌、卵巣癌、前立腺癌、脳癌、子宮頸癌および肺癌から選択される、
組成物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022177413A JP2023001236A (ja) | 2016-01-27 | 2022-11-04 | 腫瘍溶解性ウイルスベクター及びその使用 |
| JP2024028567A JP2024052881A (ja) | 2016-01-27 | 2024-02-28 | 腫瘍溶解性ウイルスベクター及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287619P | 2016-01-27 | 2016-01-27 | |
| US62/287,619 | 2016-01-27 | ||
| JP2018559162A JP2019508063A (ja) | 2016-01-27 | 2017-01-27 | 腫瘍溶解性ウイルスベクター及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559162A Division JP2019508063A (ja) | 2016-01-27 | 2017-01-27 | 腫瘍溶解性ウイルスベクター及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177413A Division JP2023001236A (ja) | 2016-01-27 | 2022-11-04 | 腫瘍溶解性ウイルスベクター及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021119797A JP2021119797A (ja) | 2021-08-19 |
| JP2021119797A5 true JP2021119797A5 (ja) | 2022-02-18 |
| JP7174109B2 JP7174109B2 (ja) | 2022-11-17 |
Family
ID=57995301
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559162A Pending JP2019508063A (ja) | 2016-01-27 | 2017-01-27 | 腫瘍溶解性ウイルスベクター及びその使用 |
| JP2021089151A Active JP7174109B2 (ja) | 2016-01-27 | 2021-05-27 | 腫瘍溶解性ウイルスベクター及びその使用 |
| JP2022177413A Withdrawn JP2023001236A (ja) | 2016-01-27 | 2022-11-04 | 腫瘍溶解性ウイルスベクター及びその使用 |
| JP2024028567A Pending JP2024052881A (ja) | 2016-01-27 | 2024-02-28 | 腫瘍溶解性ウイルスベクター及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559162A Pending JP2019508063A (ja) | 2016-01-27 | 2017-01-27 | 腫瘍溶解性ウイルスベクター及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177413A Withdrawn JP2023001236A (ja) | 2016-01-27 | 2022-11-04 | 腫瘍溶解性ウイルスベクター及びその使用 |
| JP2024028567A Pending JP2024052881A (ja) | 2016-01-27 | 2024-02-28 | 腫瘍溶解性ウイルスベクター及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10391132B2 (ja) |
| EP (2) | EP3408382B1 (ja) |
| JP (4) | JP2019508063A (ja) |
| KR (1) | KR20180136435A (ja) |
| CN (2) | CN116904404A (ja) |
| AR (1) | AR107469A1 (ja) |
| AU (1) | AU2017212713B2 (ja) |
| BR (1) | BR112018015390A2 (ja) |
| CA (1) | CA3011933A1 (ja) |
| DK (1) | DK3408382T3 (ja) |
| ES (1) | ES2919953T3 (ja) |
| IL (2) | IL260790B (ja) |
| MX (1) | MX2018009126A (ja) |
| PT (1) | PT3408382T (ja) |
| RU (2) | RU2749050C2 (ja) |
| SG (2) | SG10202107138TA (ja) |
| TW (1) | TWI798168B (ja) |
| WO (1) | WO2017132552A1 (ja) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018009126A (es) | 2016-01-27 | 2019-08-21 | Oncorus Inc | Vectores virales oncoliticos y usos de estos. |
| MX2019000252A (es) | 2016-06-30 | 2019-10-09 | Oncorus Inc | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. |
| US10682425B2 (en) | 2016-12-14 | 2020-06-16 | The Regents Of The University Of California | Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them |
| JP6832422B2 (ja) * | 2017-04-19 | 2021-02-24 | 国立大学法人 東京大学 | 遺伝子改変コクサッキーウイルス及び医薬組成物 |
| CN110546263B (zh) * | 2017-04-28 | 2024-03-05 | 东丽株式会社 | 用于检测卵巢肿瘤的试剂盒、装置和方法 |
| CA3070299A1 (en) | 2017-07-26 | 2019-01-31 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| EP3681998A1 (en) | 2017-09-11 | 2020-07-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Tumor organoid model |
| TWI666321B (zh) * | 2017-10-23 | 2019-07-21 | 大陸商深圳市亦諾微醫藥科技有限公司 | 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構 |
| CN107723367A (zh) * | 2017-10-27 | 2018-02-23 | 青岛大学 | miRNA‑885‑3p的应用和应用其的产品 |
| CN107674918A (zh) * | 2017-11-10 | 2018-02-09 | 上海交通大学医学院 | has‑mir‑195‑5p作为生物标志物在制备肺癌诊断试剂盒中的应用 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| CN111954535A (zh) * | 2018-02-19 | 2020-11-17 | 联合治疗公司 | 用于编码核糖核酸的器官保护性表达和调节的组合物和方法 |
| EP3775217A4 (en) | 2018-04-10 | 2022-06-01 | Ottawa Hospital Research Institute | MICRORNA-BASED COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES |
| MA52542A (fr) * | 2018-04-13 | 2021-02-24 | Bluebird Bio Inc | Thérapie cellulaire adoptive |
| CN108707625B (zh) * | 2018-07-03 | 2021-09-21 | 云笛生物科技有限公司 | mir-124和HER2-shRNA双基因表达盒病毒载体、构建方法、病毒、应用 |
| CN109091492A (zh) * | 2018-08-02 | 2018-12-28 | 广州安镝声生物医药科技有限公司 | lncRNA H19的靶miRNA miR-106b-5p及其应用 |
| CN109091491A (zh) * | 2018-08-02 | 2018-12-28 | 广州安镝声生物医药科技有限公司 | lncRNA H19的靶miRNA miR19a-3p及其应用 |
| CN111117973A (zh) * | 2018-10-30 | 2020-05-08 | 中国科学院武汉病毒研究所 | 一种受microRNA调控的重组溶瘤肠道病毒71型及应用 |
| US20210403950A1 (en) * | 2018-11-13 | 2021-12-30 | Oncorus, Inc. | Encapsulated polynucleotides and methods of use |
| TWI690597B (zh) * | 2018-11-14 | 2020-04-11 | 國立中央大學 | 泌尿上皮癌的檢測套組及檢測方法 |
| EP3886860A4 (en) * | 2018-11-29 | 2022-08-03 | Virogin Biotech Canada Ltd | HSV VECTOR WITH REDUCED NEUROTOXICITY |
| US20220025338A1 (en) * | 2018-12-06 | 2022-01-27 | National Cancer Center | Composition comprising nc886 for improving oncolytic virus activity or production |
| US20220117902A1 (en) * | 2019-01-04 | 2022-04-21 | Oncorus, Inc. | Encapsulated rna polynucleotides and methods of use |
| CN109762903B (zh) * | 2019-01-31 | 2022-02-01 | 山东大学齐鲁医院 | miR-1246和/或TERF2IP在诊治胶质瘤中的应用 |
| CN110283794B (zh) * | 2019-05-30 | 2021-04-23 | 伍泽堂 | 重组溶瘤病毒以及制备方法、应用和药物 |
| CN112011570B (zh) * | 2019-05-31 | 2023-04-18 | 北京合生基因科技有限公司 | 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用 |
| US20220356529A1 (en) * | 2019-07-16 | 2022-11-10 | Université Cote D'azur | Method of assessing the sensitivity or resistance of a subject to an oncolytic virus, recombinant virus, preparation and uses thereof |
| EP4009996A4 (en) * | 2019-08-05 | 2023-09-27 | Virogin Biotech Canada Ltd | GENETICALLY MODIFIED ENTEROVIRUS VECTORS |
| CN110468132B (zh) * | 2019-08-15 | 2022-11-25 | 西南大学 | 一种sgRNA及转基因表达载体、表达品系、筛选方法 |
| CN110433171B (zh) * | 2019-08-20 | 2022-08-19 | 中山大学附属第六医院 | miRNA-1293在制备抗结直肠肿瘤药物中的应用 |
| CN114765990A (zh) | 2019-10-10 | 2022-07-19 | 昂克诺斯公司 | 双重病毒和双重溶瘤病毒以及治疗方法 |
| KR102320430B1 (ko) * | 2020-01-29 | 2021-11-03 | 서울대학교병원 | 수모세포종에 대한 miR-135b, miR-135a 및 이들의 표적 유전자 AMOTL2의 용도 |
| KR20230002611A (ko) * | 2020-04-14 | 2023-01-05 | 아이드제노시쉐 테크니쉐 훽슐레 쥐리히 | 세포 분류기 회로 및 그의 사용 방법 |
| CN113583977A (zh) * | 2020-04-30 | 2021-11-02 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| WO2021244628A1 (zh) * | 2020-06-05 | 2021-12-09 | 上海宝济药业有限公司 | 一种酶和病毒的药物组合及其应用 |
| WO2022035621A1 (en) | 2020-07-31 | 2022-02-17 | Combined Therapeutics, Inc. | Compositions and methods for improved vaccination |
| WO2022100898A1 (en) * | 2020-11-13 | 2022-05-19 | Technische Universität Berlin | Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas |
| CN116744951A (zh) * | 2020-12-25 | 2023-09-12 | 苏州系统医学研究所 | 一种包含溶瘤病毒的组合物及其在肿瘤治疗中的应用 |
| WO2023034867A1 (en) * | 2021-08-31 | 2023-03-09 | Oncorus, Inc. | Engineered oncolytic herpesviruses |
| CN113637761A (zh) * | 2021-10-15 | 2021-11-12 | 北京百奥思科生物医学技术有限公司 | 用于黑色素瘤诊断和治疗的miRNA标志物及其相关产品 |
| WO2023142040A1 (en) * | 2022-01-29 | 2023-08-03 | Virogin Biotech Canada Ltd. | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors |
| CN115381849A (zh) * | 2022-06-27 | 2022-11-25 | 浙江大学 | 抗口腔肿瘤药物活性成分及其用途 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
| JPH0668B2 (ja) | 1985-08-30 | 1994-01-05 | 財団法人化学及血清療法研究所 | 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| US5849571A (en) | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| DK0641192T3 (da) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Anordning til transmucosal lægemiddelafgivelse |
| US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6261552B1 (en) | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
| GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| WO1999006583A1 (en) | 1997-07-31 | 1999-02-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| ATE305510T1 (de) | 1997-12-17 | 2005-10-15 | Immunex Corp | Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden |
| EP1002864A1 (en) | 1998-11-10 | 2000-05-24 | Universita' degli studi di Bologna | HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
| US6897057B1 (en) | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
| GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| US7749745B2 (en) | 2001-03-27 | 2010-07-06 | Georgetown University | Viral vectors and their use in therapeutic methods |
| WO2002088327A1 (en) | 2001-04-06 | 2002-11-07 | Mount Sinai School Of Medicine Of New York University | Methods for viral oncoapoptosis in cancer therapy |
| PL373594A1 (en) | 2001-10-04 | 2005-09-05 | Immunex Corporation | Ul16 binding protein 4 |
| KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신 |
| US8927251B2 (en) | 2002-10-07 | 2015-01-06 | The University Of Chicago | Targeting of herpes simplex virus to specific receptors |
| GB0406389D0 (en) | 2004-03-22 | 2004-04-21 | Istituto Superiore Di Sanito | Recombinant herpes simplex virus and uses therefor |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| US8236298B2 (en) | 2004-08-20 | 2012-08-07 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
| US20070207124A1 (en) | 2004-10-28 | 2007-09-06 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| CN101132798B (zh) | 2005-01-17 | 2011-04-27 | 溶瘤病毒有限公司 | 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物 |
| ES2564823T3 (es) | 2005-05-27 | 2016-03-29 | Ospedale San Raffaele S.R.L. | Vector génico que comprende miARN |
| ES2398918T3 (es) | 2005-08-26 | 2013-03-22 | Dupont Nutrition Biosciences Aps | Un método y una ordenación para soportar verticalmente elementos de resistencia eléctrica pendientes |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| US20080008686A1 (en) | 2006-07-10 | 2008-01-10 | The Brigham And Women's Hospital, Inc. | Tetracycline repressor regulated oncolytic viruses |
| AU2007284748B2 (en) | 2006-08-11 | 2013-05-16 | Corteva Agriscience Llc | Zinc finger nuclease-mediated homologous recombination |
| EP2125032A4 (en) | 2007-02-20 | 2011-02-23 | Mayo Foundation | TREATMENT OF CANCER USING VIRAL NUCLEIC ACID |
| WO2008141151A2 (en) | 2007-05-09 | 2008-11-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
| WO2008143875A1 (en) | 2007-05-14 | 2008-11-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
| WO2009111892A1 (en) | 2008-03-14 | 2009-09-17 | Ottawa Health Research Institute | Microrna mediated oncolytic targeting |
| EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
| PT2293804E (pt) | 2008-05-29 | 2013-08-29 | Univ Bologna Alma Mater | Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação |
| GB0810912D0 (en) | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
| WO2010011961A2 (en) | 2008-07-25 | 2010-01-28 | University Of Georgia Research Foundation, Inc. | Prokaryotic rnai-like system and methods of use |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
| US10662227B2 (en) | 2008-11-07 | 2020-05-26 | Dupont Nutrition Biosciences Aps | Bifidobacteria CRISPR sequences |
| JP2012520085A (ja) | 2009-03-13 | 2012-09-06 | エーゲン、インコーポレイテッド | 生物活性ｒｎａの送達のための組成物及び方法 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| JP5652830B2 (ja) | 2010-04-09 | 2015-01-14 | 国立大学法人 東京大学 | マイクロｒｎａ制御組換えワクシニアウイルス及びその使用 |
| WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
| WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
| EA201390586A1 (ru) | 2010-10-20 | 2014-11-28 | ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС | Последовательности crispr-cas lactococcus |
| BR112013025567B1 (pt) | 2011-04-27 | 2021-09-21 | Amyris, Inc | Métodos para modificação genômica |
| WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| EP2591796A1 (en) | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
| JP6489353B2 (ja) | 2011-10-11 | 2019-03-27 | ウニヴェルズィテート チューリッヒ | 腫瘍療法のためのｉｌ−１２とｔ細胞阻害分子遮断薬とを含む医薬組成物 |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| US20140363469A1 (en) * | 2012-01-19 | 2014-12-11 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
| KR101833589B1 (ko) | 2012-02-24 | 2018-03-02 | 프레드 헛친슨 켄서 리서치 센터 | 이상혈색소증 치료를 위한 조성물 및 방법 |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| RU2015132436A (ru) | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
| RU2716421C2 (ru) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов |
| CA2918535A1 (en) | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
| MX2016005488A (es) | 2013-10-28 | 2016-10-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vector hsv oncolitico. |
| EP3441084A1 (en) | 2014-02-27 | 2019-02-13 | Viralytics Limited | Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer |
| CA2954841A1 (en) | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
| EP3268034A4 (en) | 2015-03-05 | 2018-11-14 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
| US10083137B2 (en) | 2015-04-02 | 2018-09-25 | Atmel Corporation | Peripheral interface circuit for serial memory |
| WO2017070110A1 (en) | 2015-10-19 | 2017-04-27 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| BR112018013930A2 (pt) | 2016-01-08 | 2018-12-11 | Replimune Limited | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus |
| MX2018009126A (es) | 2016-01-27 | 2019-08-21 | Oncorus Inc | Vectores virales oncoliticos y usos de estos. |
| JP7208492B2 (ja) | 2016-03-10 | 2023-01-19 | シージー オンコロジー， インコーポレイテッド | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| CN112575036A (zh) | 2016-04-22 | 2021-03-30 | 深圳市亦诺微医药科技有限公司 | I型单纯疱疹病毒载体及重组溶瘤性i型单纯疱疹病毒 |
| JP7200104B2 (ja) | 2016-08-01 | 2023-01-06 | ヴァイロジン バイオテック カナダ リミテッド | 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター |
| CN110050062A (zh) | 2016-08-09 | 2019-07-23 | 阿尔莫哈纳德·阿尔卡亚尔 | 表达il12的溶瘤弹状病毒 |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| US20190275092A1 (en) | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| WO2018118967A1 (en) | 2016-12-21 | 2018-06-28 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CA3070299A1 (en) | 2017-07-26 | 2019-01-31 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
-
2017
- 2017-01-27 MX MX2018009126A patent/MX2018009126A/es unknown
- 2017-01-27 SG SG10202107138TA patent/SG10202107138TA/en unknown
- 2017-01-27 DK DK17704150.6T patent/DK3408382T3/da active
- 2017-01-27 JP JP2018559162A patent/JP2019508063A/ja active Pending
- 2017-01-27 EP EP17704150.6A patent/EP3408382B1/en active Active
- 2017-01-27 RU RU2018130673A patent/RU2749050C2/ru active
- 2017-01-27 WO PCT/US2017/015417 patent/WO2017132552A1/en active Application Filing
- 2017-01-27 BR BR112018015390-7A patent/BR112018015390A2/pt active Search and Examination
- 2017-01-27 PT PT177041506T patent/PT3408382T/pt unknown
- 2017-01-27 ES ES17704150T patent/ES2919953T3/es active Active
- 2017-01-27 CA CA3011933A patent/CA3011933A1/en active Pending
- 2017-01-27 CN CN202211588793.4A patent/CN116904404A/zh active Pending
- 2017-01-27 AR ARP170100218A patent/AR107469A1/es unknown
- 2017-01-27 EP EP22161034.8A patent/EP4089166A1/en active Pending
- 2017-01-27 AU AU2017212713A patent/AU2017212713B2/en not_active Expired - Fee Related
- 2017-01-27 KR KR1020187024583A patent/KR20180136435A/ko active Search and Examination
- 2017-01-27 CN CN201780019076.0A patent/CN108884448B/zh active Active
- 2017-01-27 RU RU2021114137A patent/RU2021114137A/ru unknown
- 2017-01-27 SG SG11201806134SA patent/SG11201806134SA/en unknown
- 2017-02-02 TW TW106103584A patent/TWI798168B/zh active
-
2018
- 2018-07-26 IL IL260790A patent/IL260790B/en unknown
- 2018-07-27 US US16/047,499 patent/US10391132B2/en active Active
-
2019
- 2019-07-10 US US16/507,789 patent/US11452750B2/en active Active
-
2021
- 2021-05-27 JP JP2021089151A patent/JP7174109B2/ja active Active
-
2022
- 2022-01-25 IL IL290102A patent/IL290102B2/en unknown
- 2022-08-18 US US17/820,694 patent/US20230115116A1/en active Pending
- 2022-11-04 JP JP2022177413A patent/JP2023001236A/ja not_active Withdrawn
-
2024
- 2024-02-28 JP JP2024028567A patent/JP2024052881A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021119797A5 (ja) | ||
| RU2021114137A (ru) | Онколитические вирусные векторы и их применение | |
| Ma et al. | Oncolytic herpes simplex virus and immunotherapy | |
| Roizman | The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. | |
| Leib et al. | Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo | |
| Kanai et al. | Effect of γ34. 5 deletions on oncolytic herpes simplex virus activity in brain tumors | |
| JP2020532951A5 (ja) | ||
| Zajac et al. | Biology of bovine herpesvirus 5 | |
| Xu et al. | Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development | |
| US11680248B2 (en) | Recombinant herpes simplex virus and use thereof | |
| US7731952B2 (en) | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response | |
| WO2007052029A1 (en) | Oncolytic herpes virus vectors | |
| EP2213300B1 (en) | Composition and method for treating cancer using herpes virus | |
| RU2020108004A (ru) | Онколитические вирусные векторы и их применение | |
| JP2003502008A5 (ja) | ||
| EP0517859A4 (en) | Oligonucleotide therapies for modulating the effects of herpesviruses | |
| AU772471B2 (en) | Treatment of tumors with genetically engineered herpes virus | |
| Watanabe | Medical application of herpes simplex virus | |
| US20230026342A1 (en) | New generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use | |
| Marconi et al. | HSV as a vector in vaccine development and gene therapy | |
| Argnani et al. | Replication-competent herpes simplex vectors: design and applications | |
| He et al. | DPV UL41 gene encoding protein induces host shutoff activity and affects viral replication | |
| Royer et al. | Impact of type I interferon on the safety and immunogenicity of an experimental live-attenuated herpes simplex virus 1 vaccine in mice | |
| Advani et al. | Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications | |
| Marconi et al. | HSV as a vector in vaccine development and gene therapy |